Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
World Preview 2023: Pharma's Age of Uncertainty
The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large M&A to spur growth, are getting a serious shake-up. From the FDA's shifting temperament and the ripple effects of the IRA, commercial disruptions, dealmaking ambiguities and…
Report library
H1 2023 Round Up Infographic
As we barrel into the second half of the year, it’s time to look back and make sense of what just happened. Download our infographic for a quick, data-packed overview of…
World Preview 2023 Infographic
Step into Pharma’s Age of Uncertainty, where all is in flux. From the FDA's shifting mood and the ripple effects of the IRA to commercial upheavals, dealmaking…
H1 Round Up: The haves and the have-nots
Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…
ADA/EASL eBook
June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…
ASCO 2023 Round Up
The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting in Chicago, where we've been reporting on all the big data drops and breakthroughs in cancer…
Biopharma Dealmaking In 2023: The Story So Far
Bio International marks the almost-halfway stage of the year. Representatives from big pharma, single-asset biotechs and everyone in between come together to meet, learn…
Pharma’s Biggest Spenders 2022 Infographic
As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second…
Gene Editing: Overhyped or Unstoppable Tide?
It’s a decade since Crispr first hit the headlines and now the first product using the approach is on the verge of approval. By pharma standards, this is breakneck speed…
Q1 2023 Round Up: And so it continues...
2022 was a rough year for much of the pharma sector, with limited M&A, IPO, and venture financing activity. With Q1 now over, are we expecting to see an improvement…
Quarter 1 Round up 2023 Infographic
Pharma has had a tough go of it over the past year, with limited M&A, IPO, and venture financing activity. As Q1 draws to a close, many are wondering if the sector is…